茂化實華(000637.SZ)：擬參與益生堂生物、益生堂藥業公開招募重整投資人遴選
格隆匯5月28日丨茂化實華(000637.SZ)公佈，公司為了開拓新的經營領域和轉型發展，擬由控股子公司茂名實華東成化工有限公司(以下簡稱：東成公司)參與益生堂生物、益生堂藥業公開招募重整投資人遴選。
東成公司應《公吿》和《説明》要求，分別提供《深圳市益生堂生物企業有限公司破產重整案重整預案》和《深圳市益生堂藥業有限公司破產重整案重整預案》。東成公司重整預案明確：擬將為益生堂生物提供人民幣8000萬元資金用於清償益生堂生物公司的債務(包括税款債權、破產費用、共益債務、普通債務以及享有優先受償權的債權【如有】)；擬將為益生堂藥業提供人民幣12000萬元資金用於清償益生堂藥業的債務(包括税款債權、破產費用、共益債務、普通債務)。綜上，東成公司以擬將共計提供2億元人民幣的重整預案，參與益生堂生物和益生堂藥業重整和重整投資人遴選。
根據《深圳益生堂生物企業有限公司重整案深圳益生堂藥業有限公司重整案聯合招募重整投資人的公吿》和《深圳益生堂生物企業有限公司重整案深圳市益生堂藥業有限公司重整案聯合招募重整投資人的説明》，深圳益生堂生物企業有限公司(“益生堂生物”)是一家位於深圳市的醫藥研發、生產、銷售企業，公司因保健產品轉型，前期研發費用的投入及歷年累積的債務造成公司經營困難。
深圳市益生堂藥業有限公司(“益生堂藥業”)於1983年8月5日核准成立，經營範圍為軟膠囊劑、片劑、膠囊劑、顆粒劑、糖漿劑、口服液等，因廠區建設資金佔用及發生意外事故導致公司生產設備毀損，陷入經營困難和財務危機。
2020年12月8日，深圳市中級人民法院依法裁定受理對益生堂生物、益生堂藥業破產重整的申請【案號：(2021)粵03破1號、2號】，並指定深圳市金大安清算事務有限公司擔任兩公司管理人。
為聯合推進益生堂生物、益生堂藥業重整工作，促進益生堂生物、益生堂藥業重整成功，實現社會資源的優化配置，管理人本着公開、公平、公正、擇優的原則，面向社會公開招募重整投資人蔘與益生堂生物、益生堂藥業重整事務，以期藉助重整投資人的資金實力和資源優勢為益生堂生物和益生堂藥業籌集償債資金、恢復正常經營秩序，實現重整再生的目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
